Used to classify article posts by terms used for medical conditions. It’s mostly aimed at practitioners and physicians.
Trends in Molecular Medicine, February 2002
—
Mounting in vitro and in vivo data suggest that the endocannabinoids anandamide and 2-arachidonoyl glycerol, as well as some plant and synthetic cannabinoids, have neuroprotective effects following brain injury. Cannabinoid receptor agonists inhibit glutamatergic synaptic tran…
BJOG : an international journal of obstetrics and gynaecology, January 2002
—
OBJECTIVE: To document the prevalence of cannabis use in a large sample of British women studied during pregnancy, to determine the association between cannabis use and social and lifestyle factors and assess any independent effects on pregnancy outcome. DESIGN: Self-completed…
Journal of Cannabis Therapeutics, 2002
—
The Missoula Chronic Clinical Cannabis Use Study was proposed to investigate the therapeutic bepnefits and adverse effects of prolonged use of “medical marijuana” in a cohort of seriously ill patients. Use of cannabis was approved through the Compassionate Inves-tigational New…
Neurotoxicology and teratology, January-February 2001
—
In spite of marihuana being the most widely used illegal drug among women of reproductive age, there is a relative paucity of literature dealing with the neurobehavioral consequences in offspring–particularly the longer-term effects. However, there is a degree of consistency…
Endocrinology, January 2000
—
Anandamide and 2-arachidonoylglycerol (2-AG), two endogenous ligands of the CB1 and CB2 cannabinoid receptor subtypes, inhibit the proliferation of PRL-responsive human breast cancer cells (HBCCs) through down-regulation of the long form of the PRL receptor (PRLr). Here we rep…
PNAS, 7 July 1998
—
Anandamide was the first brain metabolite shown to act as a ligand of “central” CB1 cannabinoid receptors. Here we report that the endogenous cannabinoid potently and selectively inhibits the proliferation of human breast cancer cells in vitro. Anandamide dose-dependently inhi…
NIDA research monograph, 1996
—
INTRODUCTION: In considering the relationship between marijuana use during pregnancy and the impact of such use upon the behavioral outcome of the young children of these pregnancies, the paucity of objective information is striking and, from one point of view, quite surprisin…
American Journal of Obstetrics and Gynecology, January 1995
—
OBJECTIVE: Our aim was to evaluate prospectively the effects of cocaine and marijuana use on pregnancy outcomes. STUDY DESIGN: A prospective multicenter cohort study was conducted at seven university-based prenatal clinics in the United States from 1984 to 1989. The cohort des…
Pediatrics, February 1994
—
OBJECTIVE: To identify neurobehavioral effects of prenatal marijuana exposure on neonates in rural Jamaica. DESIGN: Ethnographic field studies and standardized neuro-behavior assessments during the neonatal period. SETTING: Rural Jamaica in heavy-marijuana-using population. PA…
The West Indian medical journal, September 1991
—
This research provides data on the development of 59 Jamaican children, from birth to age 5 years, whose mothers used marijuana during pregnancy. Approximately one-half of the sample used marijuana during pregnancy and were matched with non-users according to age, parity, and…
Neurotoxicology and teratology, March-April 1990
—
Prenatal marijuana exposure is associated with adverse perinatal effects. Very little is known about the effect of postnatal marijuana exposure on infant development. Postnatal exposure can result from maternal use of marijuana during lactation. Delta-9-tetrahydrocannabinol (T…
Proceedings of the National Academy of Sciences, March 1990
—
[3H]CP 55,940, a radiolabeled synthetic cannabinoid, which is 10-100 times more potent in vivo than delta 9-tetrahydrocannabinol, was used to characterize and localize a specific cannabinoid receptor in brain sections. The potencies of a series of natural and synthetic cannabi…